Evaluating the ICCAN program's impact on cancer treatment and quality of life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
This study is testing whether the ICCAN program can help cancer patients complete their treatment and improve their quality of life compared to regular hospital services.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 347 (estimated) |
| Ages | 21 Years to 80 Years |
| Sex | All |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 11 sites (Basking Ridge, New Jersey and 10 other locations) |
| Trial ID | NCT01742143 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the effectiveness of the Integrated Cancer Care Access Network (ICCAN) program in improving treatment completion and quality of life for cancer patients. It compares the ICCAN program to standard hospital services available in New York City, such as social work and patient navigation. Participants include cancer patients currently undergoing or scheduled to begin chemotherapy or radiation therapy. The study will track outcomes over a one-year period to determine the program's impact.
Who should consider this trial
Good fit: Ideal candidates are cancer patients aged 21-80 who are currently receiving or scheduled to begin chemotherapy or radiation therapy.
Not a fit: Patients who are not currently undergoing chemotherapy or radiation therapy, or those who are only scheduled for surgery, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance cancer treatment completion rates and improve the quality of life for patients undergoing therapy.
How similar studies have performed: Other studies have shown positive outcomes with integrated care approaches in cancer treatment, suggesting potential success for this program.
Eligibility criteria
Show full inclusion / exclusion criteria
Participant Inclusion Criteria: Patient is eligible if he/she is * fluent in English, Spanish, or Mandarin * between the ages of 21-80 years old * cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or * scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients) * planning on remaining in the area for at least 1 year Clinician is eligible if he/she: * Has an MD or DO degree * Is the treating physician providing care to a patient enrolled to the study ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report: * Is 18 - 85 years of age * Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer * Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records). * Is treated in the NY metropolitan area * Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income \< 200% of federal poverty level) * Has English or Spanish proficiency * Agrees to be audio-recorded ICCAN-IO Phase 2: Pilot RCT, participant is eligible if he/she per EMR or self-report: * Is 18 - 85 years of age * Has stage II-III TNBC * Treated at MSK Manhattan or OneMSK regional sites * Self identifies as Black or Hispanic, and/or is low SES (low SES will be defined as household income \< 200% of federal poverty level) * Has English or Spanish proficiency * Agrees to be audio-recorded ICCAN-IO process evaluation study team participants only: * Staff member who serves as an Access Facilitator * Agrees to be audio-recorded Participant Exclusion Criteria: Patient is ineligible is he/she is: * Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report: * Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent * Participants or family members who are participating in MSK IHCD studies related to social determinants of health ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report: * Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent * Participants or family members who are participating in MSK IHCD studies related to social determinants of health
Where this trial is running
Basking Ridge, New Jersey and 10 other locations
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey, United States (Recruiting)
- Lutheran Medical Center — Brooklyn, New York, United States (Active_not_recruiting)
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) — Commack, New York, United States (Recruiting)
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison, New York, United States (Recruiting)
- City College of New York (Data Collection AND Data Analysis) — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities) — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) — Rockville Centre, New York, United States (Recruiting)
- Lincoln Hospital and Mental Health Center — The Bronx, New York, United States (Active_not_recruiting)
Study contacts
- Principal investigator: Francesca Gany, MD, MS — Memorial Sloan Kettering Cancer Center
- Study coordinator: Francesca Gany, MD, MS
- Phone: 646-888-8054
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.